Powered by

Sanofi : Dupixent(R) (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis

Aug 06, 2019 - Thomson Reuters ONE
Product Launch

Dupixent(R) (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis

- Only biologic approved in the European Union for patients aged 12 and above with moderate-to-severe atopic dermatitis

- Approval is based on Phase 3 trial results showing Dupixent significantly improved disease extent and severity, skin clearance, and itch intensity, as well as sleep and health-related quality of life

PARIS and TARRYTOWN, NY - August 6, 2019 - The...